Catabasis Using $110M Investment to Advance QLS-215 Therapy

Catabasis Using $110M Investment to Advance QLS-215 Therapy

285528

Catabasis Using $110M Investment to Advance QLS-215 Therapy

Catabasis Pharmaceuticals will use a $110 million private investment to complete preclinical and early clinical studies evaluating QLS-215, its investigational kallikrein-inhibitor therapy  for hereditary angioedema (HAE). QLS-215 became Catabasis’ lead product after it acquired the original developer, Quellis Biosciences, in January 2021. Now, the company plans to file an application requesting that QLS-215 enter clinical testing in the first half of 2022. “Our mission has always been to bring life-changing therapies to patients and families…

You must be logged in to read/download the full post.